Updated
Updated · frontline.thehindu.com · Jun 18
India Reassesses Biosafety Rules After US Discloses Funding 120 Biolabs in 30+ Countries
Updated
Updated · frontline.thehindu.com · Jun 18

India Reassesses Biosafety Rules After US Discloses Funding 120 Biolabs in 30+ Countries

2 articles · Updated · frontline.thehindu.com · Jun 18

Summary

  • US disclosures released June 12 said Washington funded more than 120 biological laboratories across 30-plus countries, with some facilities conducting gain-of-function research, prompting India to review how it governs foreign-linked pathogen work.
  • India was not publicly identified in the ODNI material, but the report says that absence does not rule out past or current US-supported labs or collaborations and makes transparency the central issue.
  • Three steps are proposed: a public registry for foreign-funded high-consequence pathogen research, a coordinated national review mechanism across agencies, and periodic scrutiny of BSL-3 and BSL-4 collaborations and overseas sample transfers.
  • India's case is shaped by earlier controversies, including the WHO-ICMR mosquito project disbanded in 1975 and later questions over the Manipal Centre for Virus Research's sample shipments and regulatory status.
  • As India expands high-containment labs and biotech capacity, the report argues Parliament should regularly review biosafety, biosecurity, data governance and international biological partnerships as matters of national security and public trust.

Insights

As US-funded biolabs are revealed, how can India protect its sovereignty from potential bio-threats?
Why is high-risk pathogen research being outsourced globally instead of secured within the US?
Is gain-of-function research a necessary tool for stopping pandemics or a catastrophic risk?